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Background: Research is ongoing to develop multipurpose vaginal rings to be used continuously for
contraception and to prevent Human Immunodeficiency Virus (HIV) infection. Contraceptive vaginal rings (CVRs) are
available in a number of countries and are most of the time used intermittently i.e. three weeks out of a 4-week
cycle. Efficacy trials with a dapivirine-containing vaginal ring for HIV prevention are ongoing and plans to develop
multi-purpose vaginal rings for prevention of both HIV and pregnancy have been elaborated. In contrast with the
CVRs, multi-purpose vaginal rings will have to be used continuously. Women who continuously use a CVR will no
longer have menses. Furthermore, some safety aspects of CVR use have never been studied in-depth in the past,
such as the impact of the vaginal ring on the vaginal microbiota, biofilm formation and induction of inflammation.
We studied acceptability and these novel aspects of safety in Rwandan women. Although significant progress has
been made over the past decade, Rwanda still has a high unmet need for contraception (with 47% unplanned
births) and a generalized HIV epidemic, and CVRs are not yet available.
Methods: We will conduct an open label, single centre, randomized controlled trial. A total of 120 HIV-negative
women will be randomized to intermittent CVR use (to allow menstruation) or continuous CVR use. Women will be
followed for a maximum of 14 weeks. In parallel, we will conduct a qualitative study using in-depth interview and
focus group discussion methodology.
Discussion: In addition to evaluating the safety and acceptability of intermittent and continuous CVR use in
Rwandan women, we hope that our findings will inform the development of future multipurpose vaginal rings, will
prepare Rwandan study populations for future clinical trials of multipurpose vaginal rings, and will pave the way for
introduction of CVRs on African markets.
Trial registration: Clinicaltrials.gov NCT01796613. Registered 14 February 2013.
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Vaginal rings are polymeric drug delivery devices de-
signed to provide controlled release of drugs for intrava-
ginal administration over extended periods of time.
Compared to systemic dosing, this maximizes efficacy at
lower doses, thereby reducing side effects [1-8]. Further-
more, the ring can stay in place for 1–3 months, which
improves adherence [9-11]. In recent years, vaginal rings* Correspondence: cschurmans@itg.be
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placement therapy in Latin America, the United States
and Europe where studies on the acceptability of the
contraceptive vaginal ring (CVR) have shown overall
good adherence and acceptability. On average, 85% of
the users were satisfied or very satisfied and 85% to 90%
would recommend the method to others [3,12].
However, CVRs are not yet on the market in any
African country. Limited vaginal ring acceptability
data are available in the context of HIV prevention re-
search. A study by the International Partnership fortral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ated the acceptability of a vaginal ring without any active
drugs [13]. The study found that the vast majority of
women felt comfortable inserting and removing the ring,
acceptability increased with prolonged use, and only one
male sexual partner felt the ring during sex [14]. This pla-
cebo ring and a similar ring containing the antiretroviral
drug dapivirine are currently used in two HIV prevention
efficacy trials in African women (the IPM027 [15] and
MTN020 [16] trials). CONRAD is currently developing a
contraceptive/microbicide CVR (similar to NuvaRing®)
and reformulating tenofovir gel with contraceptive proper-
ties for use with the SILCS diaphragm [17]. Given these
developments, we believe that single-purpose and/or
multi-purpose vaginal rings will eventually be introduced
in African settings.
A multi-purpose vaginal ring will have to be used con-
tinuously, which is different from the way CVRs cur-
rently are mostly used. Current use is intermittent, i.e.
the ring is taken out for one week after having been in
place for three weeks. Women who continuously use a
CVR will no longer have menses. We need in-depth data
on the acceptability of the vaginal ring and of continu-
ous use. Gaining a better understanding of acceptability
requires the assessment of an intertwined set of variables
and constructs such as users’ personal characteristics
and factors influencing the user experience (product effi-
cacy, attributes, and price; relationship context and fac-
tors impacting on sexuality). These factors in turn are
embedded in a specific sociocultural context. The con-
ceptual framework developed by Woodsong et al. for
assessing the vaginal ring for microbicide delivery will
guide our acceptability research [18].
Bacterial vaginosis (BV) is an imbalance of the vaginal
microbiome. Epidemiological studies have shown that
women with BV are twice more likely to acquire HIV
than women without BV [19,20]. The vaginal micro-
biome can now be characterized in much more detail
using molecular methods than was previously possible
using microscopy. Very recent research has shown that
the vaginal microbiome in African women can be cate-
gorized into at least 6 different bacterial communities,
each with distinct characteristics in terms of the types
and quantities of bacteria present, whether or not in-
flammation is induced and whether there is an increased
risk for Human Immunodeficiency Virus (HIV) or other
Sexually Transmitted Infections (STIs) [21]. The pres-
ence of inflammation is particularly important because
inflammation often causes symptoms (itching, burning)
and is associated with an influx of HIV target cells e.g.
CD4+ T cells and macrophages into the genital area
[22]. It is therefore very important that any product used
inside the vagina (such as a CVR) does not cause irrita-
tion and/or inflammation.BV has also been associated with biofilm formation of
microorganisms on the vaginal epithelia and this may be
why BV recurrence rates are very high after initial suc-
cessful treatment [23,24]. BV is more common in Afri-
can and African-American women, which could be due
to the high prevalence of vaginal anaerobic bacteria that
are prone to form biofilms [25,26]. It is also well known
that biofilms easily form on the surface of catheters and
prostheses [27]. Knowledge is lacking on whether vaginal
bacteria can adhere to the ring and form a biofilm. A
small study among four non-human primates suggested
that the vaginal ring could lead to biofilm formation
[28]. We therefore need to explore the formation of bio-
films on vaginal rings in the vagina for different periods
of time. Furthermore, biofilms may hamper delivery of
the active compounds of the rings and could lead to
clinical BV (which increases risk of HIV acquisition).
Better knowledge on biofilm formation in the cervicova-
ginal context will aid further development of multi-
purpose vaginal rings.
In Africa, especially in Rwanda there is an unmet need
for contraception with 47% unplanned births and a gen-
eralized HIV epidemic [29-32]. Several large epidemio-
logical studies have suggested an increased risk of HIV
acquisition in women using high dose long-acting pro-
gestogens (the so-called ‘injectables’) [33], which means
that these may have to be replaced with other long-
acting hormonal methods such as CVRs, provided that
they do not pose an HIV acquisition risk by causing
inflammation.
The CVR that will be used in this trial is commercial-
ized under the trade name of NuvaRing®, approved since
2001 by most countries within the European Union, and
in the United Stated by the FDA. To date NuvaRing® is
available in 32 countries and used by approximately 1.5
million women. NuvaRing® contains etonogestrel/ethinyl
estradiol and is manufactured by N.V. Organon (a sub-
sidiary of Merck & Co., Inc.,), Oss, the Netherlands.
We describe here the study protocol as it was ini-
tially designed. At time of submission of this paper, the
study has started and data collection and analyses are
ongoing.Study objectives
The study will be a multidisciplinary research project with
two aims. The first aim will be to determine the safety of a
CVR in women, with an emphasis on its effect on the va-
ginal microenvironment after different durations of use:
the vaginal microbiome, biofilm formation on epithelial
cells and rings, inflammation and immune activation in
the vagina; and the second aim to investigate the feasibil-
ity, acceptability and adherence to vaginal ring use in
Rwandan women, including attitudes towards a future
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nancy and STIs.
The study objectives are described in Table 1.Methods and design
An integrated study design
The clinical trial will combine a clinical safety evaluation
of the CVR with social science research on acceptability
and adherence of ring use in Rwandan women.
This will be an open label single-centre cohort study
with the NuvaRing®. A total of 120 HIV-negative women
will be randomized to an intermittent or a continuous
regimen of ring use and will be followed for maximum
14 weeks, to determine general safety of the ring in the
African context, and to determine differences in the va-
ginal microbiome and vaginal inflammation before and
after use of a CVR (Figure 1). Qualitative research for
the social science component will be performed to ad-
dress the acceptability and adherence of intermittent or
continuous CVR use in more depth.Study participants
HIV negative, healthy women not using a modern
contraceptive method (not including barrier methods)
and who are interested in initiating hormonal contracep-
tive use, will be recruited and followed up at the Rinda
Ubuzima (RU) research clinic and laboratory in Kigali,
Rwanda. They will receive extensive counselling on all
contraceptive methods available in Rwanda and on pre-
vention of HIV and other STIs. They will be offered HIV
and STI testing and condoms free of charge. The social
science component of the acceptability study will include
in-depth interviews (IDIs) and focus group discussions
(FDGs) which will take place alongside the clinical study
(Figure 2).




To assess the impact on the vaginal microbiome of the use




To assess the general safety of the CVR.
To assess the vaginal biofilm formation according to ring use
regimen. To determine the presence or absence of a biofilm
the CVRs after intermittent or continuous use by visualization
the biofilm. To assess the impact of CVR on vaginal inflamma
and immune activation according to ring use regimen.
Exploratory
objectivesSample size and power calculation
A total of 120 women will be enrolled in the clinical
trial: 60 will be randomized to the intermittent regimen
of ring use and 60 to the continuous regimen. This clin-
ical study sample size calculation is based on the pri-
mary objective to assess the pre-post changes in the
vaginal microbiome.
We require 95% power to detect clinically important
changes in bacterial counts. Analyses of our on-going
biomarkers study showed a difference of (−)1 log in
overall Lactobacillus sp. counts and of (+)3 log in G.
vaginalis counts between participants with and without
BV as assessed by Nugent score, and standard deviations
of 1 and 3 for changes in overall Lactobacillus sp. counts
and G. vaginalis counts, respectively [34]. We have de-
fined a change in bacterial count of 50% of the observed
differences between women with and without BV as clin-
ically important. Given this, we require 52 women in
each study group. To correct for early withdrawals and
women lost-to-follow up, we will randomize 120 women
(60 in each study group) to ensure we have 104 women
with primary endpoint data available.
For the qualitative research, sample sizes will be deter-
mined by when data saturation is reached.
After pre-screening, IDIs will be conducted. Midway
through the project, FGDs (8–12 women in each group)
will be conducted as well as at the end of the project. In
addition, IDIs will be conducted with women and with
male partners of participants.Randomization and follow-up
Informed consent process
All informed consent (IC) procedures (including assess-
ment of understanding and literacy) will be conducted
by qualified staff members identified by the principal in-
vestigator (PI), in the language chosen by the partici-
pants and according to the requirements described inSocial science component
To assess the level of acceptability and reported adherence to
intermittent and continuous CVR use in women in Rwanda
To identify and describe the context specific attitudes and




To explore the women’s beliefs and expectations regarding future
potential use of a multi-purpose ring (contraception and HIV
prevention). To explore how women and men in Rwanda perceive
and experience risk related to unwanted pregnancy and HIV.
Figure 1 Schedule of the clinical study.
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the Good Clinical Practice (GCP) guidelines. Participant
information sheets and consent forms in the local lan-
guage will be provided to the study participants or le-
gally authorized representatives and witnesses for their
review. After the IC procedure, the participants and, in
case they are of minor age (age below 21 and unmarried
in Rwanda), the parents or guardians will be asked to
confirm their willingness to participate in the study by
signing (or thumb-printing whenever they are illiterate)
the consent form. The RU standard operating procedure
(SOP) for IC will be followed.
If a participant (or parent or guardian) is unable to read
or write, an independent witness will take part in the IC
discussion and his/her signature will be obtained. Partici-
pants will be informed that participation in the study is
completely voluntary and that they can withdraw from the
study at any time without any negative consequences.
Separate IC forms will be given to all study partici-
pants and partners who agree to participate in the FGDs
and IDIs.
Clinical part
This will be an open-label study because the differences
in ring use (intermittent or continuous use) cannot be
blinded. Individual participants will be randomized and
treatment allocation will be concealed until a participant
has provided informed consent, is confirmed eligible, is
included in the study and inserted the CVR.
After randomization the follow up visits will be
planned to coincide with times of removal and insertion
of the ring (Figure 2). Participants will be asked to
complete Interviewer Administered Questionnaire (IAQ)
including adherence related questions.
Every effort will be made to ensure participants adhere
to this visit schedule and in such way that their confi-
dentiality and privacy will be protected.
Social science part
Women participating in IDIs will be purposively se-
lected according to age/parity and experience withcontraception in order to have a wide variation of key
characteristics.
A sub-sample of women will be purposively selected
according to specific criteria i.e. vaginal practices, ring
removal and/or expulsions, parity and experience with
contraception to participate in FGDs.
After trial completion, women who will not yet have
participated in any other FGDs will be selected based on
ring removal and/or expulsions. Participants and part-
ners will be invited to participate in end trial IDIs.
Diagnostic tests and laboratory procedures
All treatable genital infections identified using the syn-
dromic approach and any missed infections but identi-
fied later by laboratory testing will be treated according
to RU SOPs based on national guidelines. Table 3 lists
diagnostic tests that will be performed using validated
test kits or methods, and procedures [34]. Table 4 lists
the research tests that will be performed.
Investigational product
NuvaRing® is manufactured by N.V. Organon (a subsid-
iary of Merck & Co., Inc.,), Oss, the Netherlands and
contains 11.7 mg etonogestrel and 2.7 mg ethinylestra-
diol. The CVR releases etonogestrel and ethinylestradiol
at an average amount of 0.120 mg and 0.015 mg, re-
spectively per 24 hours, over a period of 3 weeks. The
CVR is approved since 2001 by most countries within
the European Union, and in the United States by the
Food and Drug Administration.
Safety
Participants will be asked to inform the study staff of any
medical problems while they are taking part in the study.
Adverse events (AEs) will be collected until the final ring
removal visit and will also be identified during laboratory
testing, medical histories and physical examinations. Treat-
ment for AEs possibly/probably/definitely related to study
participation will be provided by the study clinic at no cost
to the participant. All clinical and laboratory toxicities will
Figure 2 Schedule of assessments.
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Table 2 In- and exclusion criteria
Inclusion criteria » Able and willing to give informed consent/assent, according to national guidelines
» Female who self-reports to be sexually active (meaning at least one penetrative vaginal coital act per month for
the last 3 months prior to screening)
» Between 18 to 35 years old, inclusive
» Currently in good physical and mental health
» Interested in initiating hormonal contraception
» Able and willing to participate in the study as required by the protocol, this includes willing to undergo HIV testing
and use a NuvaRing®
» HIV negative at screening as confirmed by rapid HIV testing
Exclusion criteria » Currently using a modern contraceptive method other than barrier methods
» Use of a hormonal contraceptive method in the three months prior to the screening visit
» Currently using antimicrobial medication
» Pregnant on urine pregnancy test
» History of cardiovascular disease
» History of hysterectomy or genital tract surgery (including cervical polypectomy, dilatation and curettage, hysteroscopy,
or laparoscopy) in the three months prior to the screening visit
» History of complications with hormonal contraception or with contra indications for the use of hormonal contraceptives such as:
o History or known predisposition for venous thrombosis
o History of migraine with focal neurological symptoms
o Diabetes mellitus with vascular involvement
o History of pancreatitis or severe hepatic disease
o Known or suspected hypersensitivity to any of the excipients of NuvaRing®
» History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding, incontinence or urge incontinence,
diagnosed chronic and/or recurrent vulvovaginal candidiasis, urethral obstruction
» Participating in other clinical studies involving investigational products
» Currently breastfeeding
» Currently a smoker
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AEs will be followed up until resolution.
Whenever a participant becomes pregnant during
the study, she will be followed up by the study team
until delivery, and the pregnancy outcome will be col-
lected and documented. Any pregnancy outcome that
meets any criteria for Serious Adverse Event (SAE)Table 3 Diagnostic tests that will be performed in the study
Facility where the tests will be
performed
Tests that will be performed
Laboratory at RU in Rwanda » Urine analysis for pregnancy usi
» HIV testing followed RU SOPs, w
HIV1/2 (Abbott Diagnostic Divisio
(Trinity, Berkeley Heights, New Jer
» Wet mount microscopy;
» HSV-2 (HerpeSelect 2 ELISA (Kal
(Spinreact Reactivos, Girona, Spain
Laboratoire National de
Référence, Kigali
» CT/NG molecular testing using
» Elisa for HIV (VIRONOSTIKA HIV
if the first 2 tests done at the laboreporting (e.g. congenital anomalies) will be reported
as SAE to the concerned bodies and included in the
study report.
All SAEs whether or not deemed drug related or ex-
pected will be reported within 24 hours (one working
day) to the pharmacovigilance of the clinical trials unit
(CTU) of ITM.ng QuickVue hCG (Quidel);
hich are based on the Rwandan national guidelines, using DetermineTM
n, Hoofddorp, The Netherlands) as first test and Uni-Gold HIV
sey, USA) as second test when the first test is reactive;
on Diagnostics) and syphilis testing assessed with RPR
), followed by TPHA (Spinreact Reactivos, Girona, Spain)
the Presto CT/NG kit of Goffin Molecular Technologies, The Netherlands;
Uni-Form II Ag/Ab, bioMérieux Marcy l'Etoile, Marcy l'Etoile, France)
ratory of RU showed discordant results.
Table 4 Research tests that will be performed in the study
Facility where the tests will be
performed
Tests that will be performed
Laboratory at RU or in another
laboratory in Rwanda
1. A vaginal smear will be used for BV diagnosis and a microscopic description of the vaginal flora. The
current gold standard for BV diagnosis in research settings is the Nugent score. This method relies on the
semi-quantification of the bacterial morphotypes observed in a vaginal smear after Gram staining. The
modified Ison & Hay grading is another system to describe the vaginal flora and provides more details on
the Lactobacillus species compared to the Nugent score. The Nugent score will be used to diagnose BV
and offer treatment to the women, whereas the modified Ison & Hay grading will be used for research
purposes only.
2. Luminex and ELISA cytokine testing will be used to identify women who had vaginal inflammation.
All samples that will be showing elevated cytokine levels, as well as an equal number of controls not
showing elevated cytokine levels, will be tested further for the presence of proteins involved in
inflammatory pathways.
HIV/STI reference laboratory at ITM 1. Vaginal swabs will be tested with molecular amplification techniques for the characterization and
quantification of the vaginal microbiome. Smears and an aliquot of the urine samples will be fixated
and shipped to ITM to study the changes in phenotype of BV-related bacteria (from dispersed forms to
adhesive forms on epithelial cells) to identify biofilm formation. Dispersed and adherent bacteria will be
assessed in a multicolour analysis with a mix of differently stained group-specific and universal bacterial
probes and visualized by confocal imaging.
2. The biofilms formed on the CVRs will be visualized using crystal violet staining and/or abbreviation.
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stitutional Review Board (IRB) of the ITM and the Ethics
Committee (EC) of the University Hospital of Antwerp
(UZA) annually and to the Rwanda National EC (RNEC)
case by case. RU will also submit annual line listings of
all AEs to the (RNEC).
An independent data safety monitor (gynecologist)
will review the SAE reports with special attention to
cardiovascular events (for example venous thrombosis)
which may be associated with the use of hormonal
contraception.
Monitoring and quality assurance
This study will be monitored by ITM in accordance with
regulations applicable to clinical trials, including GCP
and GCLP (Good Clinical Laboratory Practices) require-
ments, and sponsor-specific SOPs. The social science
component research will adhere to the guidelines estab-
lished by the American Anthropological Association.
A quality system has already been put in place at RU by
the ITM in previous collaborative projects and ITM will
ensure that all laboratory activities including specimenTable 5 Different types of databases that will be used in the
Types of database Characteristics




will be tested prior to use but w
Revisions to this database after s
that our questionnaires are not o
Laboratory databases will be developed for the laborat
double-checked manually by qua
be combined with variables from
Qualitative behavioural/adherence/
acceptability data
IDI/FGD transcripts and codingtransport, processing, testing, result reporting and storage
were conducted in accordance with clinical trial quality
requirements. The GCLP guidelines will be followed and
the laboratory will perform testing according to the SOPs
which will be documented in the analytical plan.
Data management
Due to the integration of quantitative and qualitative
methods in this study four different types of databases
will be set up (Table 5).
The clinical trial electronic case report form (eCRF)
and database will be designed by the data manager of
the CTU (ITM) who will also perform the data manage-
ment of the clinical trial in collaboration with the
assigned site staff (country coordinating investigator, PI,
data entry clerk).
Private information on trial participants will be handled
confidentially. A specific study code and initials will be
used on the trial source document template, the eCRF and
on any other paper documents or electronic files.
Access to all paper documents and electronic files will be
restricted to authorized study staff. The study computersstudy
validated prior to study start and for every modification during the study
ill not be fully validated according to a clinical trial validation protocol.
tudy start could be necessary when the initial qualitative research show
ptimal.
ory tests done in batches. Data in these databases will be entered and
lified laboratory professionals according to the study SOP. The data may
the above two databases for analysis.
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username and password.
Data registered on the source document template will
be recorded via eCRFs into the clinical trial database,
using OpenClinica. OpenClinica is the world's leading
open source clinical trials software for electronic data cap-
ture and clinical data management. OpenClinica supports
GCP quality standards, guidelines and requirements such
as the Code of Federal Regulations Title 21 part 11 (e.g.
electronic signature, electronic audit trail). The experience
in the use of an open source data management system will
strengthen the capacity of the local site.
Data analysis
Clinical analysis
The statistical analysis of the primary objective and sec-
ondary objective one of the clinical trial will be per-
formed by the study statistician at the CTU (ITM)
according to a Statistical Analysis Plan.
The objectives (Table 1) will be reached by describing
and comparing the variables of interest in women ran-
domized to either intermittent vaginal ring use (group
A) over a 12 week study period or continuous ring use
(group B) over a 13 week study period.
In general, analyses will be performed using an "as-ran-
domized" all-participants-treated approach. All women
randomized and who insert the CVR at the enrollment
visit will be included in the analysis under the group they
are randomized to, even if they discontinue before visit 2
(week 4). For the analyses requiring vaginal or urine sam-
ples, all women with available data will be used, i.e.
women without a sample prior to or during CVR use will
be excluded.
Participants in each treatment group will be described
with respect to baseline characteristics. The primary
analysis is based on the quantitative real time polymer-
ase chain reaction (qPCR) vaginal flora data. This data
will comprise different species and will be recorded at
baseline (week 0), and at 3 (group A) or 4 (group B)
time points during CVR use.
The presence/absence of each species during CVR
use will be analyzed using repeated measures logistic
regression models, with random intercepts and random
slopes over time for each woman and fixed effects for
randomization group (intercept and slope).
The incidence of signs and symptoms, study/ring use
withdrawals, adverse experiences and STIs will be com-
pared among randomization groups over the full study
period using Fisher's exact test. Changes in Nugent
scores and Ison & Hay grading of the vaginal flora will
be graphically depicted and analysed using repeated
measures (logistic) regression models.
The statistical analysis of secondary objectives 2 and 3
are research and data driven, no prior statistical analysisplan will be made but the statistical analysis methods will
be fully described in the resulting reports and/or publica-
tions. Presence/absence of dispersed/adherent form of
BV-related bacteria and of biofilms will be analyzed using
repeated measures logistic regression models.
Qualitative analysis
All IDIs and FGDs will be audio-recorded and will be
followed by a debriefing session. After transcription and
translation, data will be uploaded into Nvivo 9.
For the primary objective, the IDI and FGD data will
be analysed through a deductive, content-analytical ap-
proach to assess if the components of the theoretical
framework developed by Woodsong [9] are valid in the
given setting. New elements that emerge from the data
will be integrated into the framework. Selected statistical
analysis will be conducted on the data of the individual
asked questionnaires, the ballot box questionnaires and
the self-rating adherence scales. This quantitative ana-
lysis will be largely descriptive.
To analyse the IDIs and FGDs for the secondary objec-
tives, open coding methodology based on a data driven
framework will be developed by the research team.
A descriptive analysis of the data from the individual
asked questionnaires will be conducted to address the
exploratory objectives, in parallel with coding of the IDIs
and FGDs based on a risk perception attitude framework
supplemented by the research team as themes emerge.
All coding and analysis will be performed by at least
two qualitative researchers to compare their coding and
reach consensus on convergent issues.
Ethics
The protocol and all study documents were reviewed
and approved by the IRB of the ITM, the EC of UZA
and the RNEC, the National Health Research Committee
and to the Rwandan Ministry of Health (MoH). Ap-
proval for importing vaginal rings was obtained from the
Rwandan MoH. No study activities will be performed
before approval from all these bodies is obtained.
Yearly re-approval from the RNEC will be sought after
submission of the annual report.
The study will be carried out according to the principles
stated in the Declaration of Helsinki, all applicable national
and international regulations and International Conference
on Harmonization and World Health Organization GCP
guidelines.
Steering committee and trial management group
A Trial Management Group (TMG) will be in charge of
the day-to-day management of the clinical trial.
A Steering Committee (SC) will be set up to manage
and supervise the entire project. The SC will consist of
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institution.
Archiving
The PI and the sponsor must maintain adequate and ac-
curate records to enable the conduct of the study and
the verification of the data.
After completion of the study, the site investigator file
and the sponsor trial master file will remain available for
internal audits and/or inspections of regulatory author-
ities for a period of twenty years in accordance with the
Belgian legislation.
Discussion
Before implementing an intervention, it is beneficial to
investigate whether this intervention, if proven effective,
will be accepted and used by the local population.
Therefore a mixed method approach was chosen for our
study. However including a sociological component to a
clinical study can be challenging as sexual behavior
questioning in research trials is not straight forward due
to several factors, for example the public opinion or the
risk of being excluded from the study, and participants
may give inaccurate reports. For this reason different
sources such as the questionnaires, diary cards and data
obtained from the IDIs and FGDs will be used to tri-
angulate and assess the validity of the data.
Another challenge is to follow the protocol as designed
at the start of a clinical trial. As it is an intricate task to
predict every need that will arise during the course of
the study, it could be that, after a cautious assessment of
the pros and cons, changes are required during the
study. For our study, two main changes occurred: an
additional cervical swab taken at baseline for the rapid
detection of CT using the BioChekSwab (a rapid self-
contained, two step enzyme detection system) and the
range of male partners that were invited for an IDI was
broaden from partners from women who participated in
the end trial IDI or FGD to all partners. These amend-
ments to the protocol were submitted and approved by
all involved review bodies.
Multi-purpose rings require continuous use. However
as the CVR used in our study, the NuvaRing®, releases
the contraceptive hormones etonogestrel and ethinyles-
tradiol over a period of 3 weeks (with a maximum of
4 weeks after which the contraceptive effect cannot be
guaranteed anymore), it was not possible to implement
continuous use. Our continuous use study regimen, i.e.
replacing the ring every 3 weeks, approaches the con-
tinuous use as close as possible.
Due to the expected short recruitment period and the
use of commercially available and approved CVRs, no
formal data safety monitoring board (DSMB) will be set
up and an independent data safety monitor will beappointed. In case of major safety concerns, this person
will request the sponsor to halt recruitment of the trial
and/or to organize a formal DSMB with a complete
overview of all available safety data.
The proposed study will prepare the study community
in Rwanda for vaginal ring use. It will improve the study
instruments (particularly related to adherence and accept-
ability) of the RU research centre and will strengthen their
research capacity even further. In a wider context, the pro-
ject results will be shared within our extensive network of
microbicide researchers and in particular within the net-
work of the single- and multipurpose vaginal ring re-
searchers. Our findings will thus inform the development
of future multipurpose vaginal rings for Africa and future
vaginal ring trial design. Finally this study may lead to the
introduction of contraceptive vaginal rings on African
markets.
Study status
The study is ongoing. Data collection and data analysis
are ongoing.
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